🇺🇸

US SEC Filing Intelligence

· daily

US Executive Officer Management Changes SEC — September 17, 2026

This digest covers 30 SEC filings from September 17, 2026, focused on executive and director changes. Key themes include a wave of CEO/CFO successions, a notable shift toward independent board leadership, and a significant uptick in performance-based equity grants tied to aggressive stock price targets. The most material event is the pending $163M merger between First Reliance and Colony, now awaiting shareholder approval. While most changes are routine, the concentration of insider sales and the lack of transparency in several filings warrant caution. We identify 10 investment signals, 8 risks, and 8 opportunities, highlighting both stability plays and high-growth catalysts.

30 high priority 30 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 17, 2026

The 30 filings reveal a dynamic period of leadership transitions across US public companies, characterized by a mix of routine successions, strategic hires, and a high-profile merger. Key themes include a notable shift towards external and independent directors with deep industry expertise, significant insider buying by a new CEO, and a clear focus on growth-oriented appointments in financial services. While most changes are neutral-to-positive, the departure of a CEO amid an FTC second request for a pending merger and an unexplained officer change present specific risks. The data suggests a market rewarding companies with clear succession plans and experienced leadership, while penalizing uncertainty.

30 high priority 30 total filings
· daily

US Merger & Acquisition SEC Filings — September 17, 2026

The September 17, 2026, M&A filings reveal a market bifurcated between high-conviction, capital-intensive real estate and healthcare transactions and a flurry of SPACs struggling to complete deals or maintain compliance. The most significant capital movement is in industrial real estate, with Rexford Industrial's $1.2B portfolio sale and Surgery Partners' $796.6M hospital divestiture, both reflecting strategic portfolio realignment to optimize balance sheets. The SPAC sector shows clear distress: two SPACs (Bayview, Ribbon) made routine extension payments to buy time, Fifth Era Acquisition received a Nasdaq deficiency notice for low holder count, and Metal Sky Star fired its auditor amid going-concern warnings. The most transformative deal is Lisata Therapeutics' acquisition of Marea, which will effectively reverse-merge into a cardioendocrine pipeline, diluting legacy shareholders by over 97%. Healthy Choice Wellness Corp. is executing a high-risk reverse merger into a data center project with no revenue and a $27.5M working capital deficit, while Predictive Oncology sold its legacy diagnostics business to complete its pivot to GPU-as-a-Service. Period-over-period data is limited in these 8-K filings, but the forward-looking guidance and capital allocation patterns are rich: Rexford is aggressively buying back stock ($505M YTD), while Lisata's $225M PIPE signals strong institutional appetite for the combined entity's pipeline catalysts in Q4 2027.

10 high priority 10 total filings
· daily

Biotech Small-Cap Approvals — September 16, 2026

Over September 11-14, 2026, the FDA approved 4 products, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 4 'Other' approvals. The period delivered two high-conviction bullish signals—APITEGROMAB-MSTN (ISEMBYLD) from SCHOLAR ROCK INC, an NME with Priority Review and Orphan designations, and FLORETYROSINE F 18 (PIXCLARA) from TELIX PHARMACEUTICALS US INC, also an NME with Priority Review and Orphan status. Two neutral signals came from generic/biosimilar approvals of EPINEPHRINE by ZYDUS PHARMS and DASATINIB by MSN. The dominant theme is a lack of pure oncology NME clustering; however, both approved NMEs leverage Orphan exclusivity, signaling continued FDA appetite for rare disease therapies. Key risk: no peak sales or pricing data is disclosed for any approval, impairing near-term commercial valuation estimates.

4 total filings
· daily

NME Blockbuster Approvals — September 16, 2026

In the period of September 16, 2026, the FDA approved two NMEs, both receiving Priority Review and Orphan Drug designations, signaling strong regulatory support for novel therapies in niche indications. The approvals include APITEGROMAB-MSTN (ISEMBYLD) from Scholar Rock Inc and FLORETYROSINE F 18 (PIXCLARA) from Telix Pharmaceuticals US Inc, both classified as bullish with high materiality. The highest-conviction signal is APITEGROMAB-MSTN, a potential first-in-class therapy for a rare disease, though commercial details remain undisclosed. A key risk is the lack of disclosed peak sales estimates and exclusivity periods, which limits near-term revenue forecasting for investors.

2 total filings
· daily

Orphan Drug Approvals — September 16, 2026

The September 16, 2026 orphan drug approval stream delivered three approvals, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion), with a bullish signal mix of 3-0-0. The dominant theme is precision medicine in oncology and rare diseases, highlighted by two NME approvals (APITEGROMAB-MSTN from Scholar Rock and FLORETYROSINE F 18 from Telix) and one label expansion (LENIOLISIB PHOSPHATE from Pharming). The highest-conviction signal is APITEGROMAB-MSTN (ISEMBYLD), a first-in-class NME with Priority Review and Orphan status, indicating significant commercial potential for Scholar Rock in a niche market. Key watch items include the lack of disclosed commercial data (peak sales, pricing) and the regulatory classification of these approvals, which may carry post-marketing requirements or accelerated approval risks.

3 total filings
· daily

New Drug Approvals (Original) — September 16, 2026

During the September 16, 2026 period, the FDA approved four products, all classified as 'Other' (non-standard NME/biosimilar/label expansion) but including two high-conviction NMEs with Priority Review and Orphan Drug designations. The dominant theme is the approval of novel, targeted therapies for rare diseases, with SCHOLAR ROCK INC's APITEGROMAB-MSTN (ISEMBYLD) and TELIX PHARMACEUTICALS US INC's FLORETYROSINE F 18 (PIXCLARA) representing the strongest bullish signals. These NMEs signal significant commercial potential in niche, high-priced orphan markets. The two biosimilar approvals (EPINEPHRINE from ZYDUS PHARMS and DASATINIB from MSN) are neutral events, reflecting routine market entry for established molecules. Key risk: the lack of disclosed commercial data (peak sales, pricing) for all approvals limits precise valuation, but the dual NME approvals underscore strong sponsor pipeline execution in rare disease diagnostics and therapeutics.

4 total filings
· daily

Federal Construction & Infrastructure Contracts — September 16, 2026

This digest covers a single $378.1 million civilian contract awarded by the Department of State to CADDELL CONSTRUCTION CO. (DE), LLC for a new embassy compound in Brasilia, Brazil. The award is defense-adjacent (diplomatic infrastructure) but not a direct Department of Defense contract, and it represents a stable, long-term revenue stream for Caddell Construction through 2029. The highest-conviction signal is the neutral, stable nature of the award—a firm-fixed-price, full-and-open competition win that provides revenue visibility but carries overseas execution risk. Key risk: the fixed-price structure exposes Caddell to cost overruns on a complex foreign project, while no follow-on awards in this period limit diversification.

1 total filings
· daily

New Federal Contractors — September 16, 2026

The sole contract in this digest is a $378.1 million firm-fixed-price award from the Department of State to Caddell Construction Co. (DE), LLC for the construction of a new U.S. embassy compound in Brasilia, Brazil, representing a 100% civilian (non-DoD) allocation. The seven-year performance period (through 2029) provides long-term revenue visibility, but the fixed-price structure and overseas execution introduce medium pricing and execution risk. The highest-conviction signal is the full-and-open competition win, indicating Caddell's strong operational capacity and competitive pricing without set-aside preferences. Key watch items include cost/schedule performance against fixed-price terms and potential modifications to realize the full contract value.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 16, 2026

The single contract in this period is a $378.1 million firm-fixed-price award to CADDELL CONSTRUCTION CO., INC. from the Department of State for constructing a new U.S. embassy compound in Brasilia, Brazil. This is a civilian-sector, non-defense contract with a neutral signal strength of 6/10, reflecting stable long-term revenue visibility offset by execution risk on a fixed-price overseas project. The seven-year performance period (2022-2029) provides predictable revenue but cost overrun risk is borne entirely by CADDELL. The key watch item is CADDELL's ability to execute on schedule and budget, as any modifications or delays would directly impact margin.

1 total filings
· daily

Contract Deobligations Alert — September 16, 2026

The sole contract in this digest is a $378.1 million firm-fixed-price award from the Department of State to Caddell Construction Co. (DE), LLC for the construction of a new embassy compound in Brasilia, Brazil, representing a 100% civilian agency allocation. This seven-year (2022-2029) full-and-open competition signals a stable, long-term revenue stream for Caddell, though the fixed-price nature and overseas execution introduce medium cost and schedule risk. The highest-conviction signal is the durability of State Department funding for diplomatic infrastructure, which suggests continued opportunities in the embassy construction sector. Key watch items include Caddell's execution performance against the fixed-price terms and any future State Department awards that could indicate market share expansion.

1 total filings
· daily

Contract Option Exercises — September 16, 2026

This digest covers a single $378 million Department of State contract option exercise to CADDELL CONSTRUCTION CO. (DE), LLC, representing the entire aggregate obligation. The contract, awarded in May 2022, is a firm-fixed-price, full-and-open competition for constructing a new embassy compound in Brasilia, Brazil over a seven-year performance period. The civilian-sector award provides long-term revenue visibility for CADDELL, but its fixed-price nature and overseas execution introduce cost-overrun and schedule risk. The strongest signal is a neutral one, with no bullish or bearish indicators; investors should monitor execution progress and potential modifications to confirm margin realization. There is a notable absence of defense-related content, so the digest is purely civilian in context.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 16, 2026

This digest covers a single $378.1 million contract awarded to CADDELL CONSTRUCTION CO. (DE), LLC by the Department of State for constructing a new embassy compound in Brasilia, Brazil. The contract is entirely civilian, representing a long-term, fixed-price revenue stream through 2029. The neutral signal reflects balanced execution risk and stable demand for diplomatic facilities. Key watch items include CADDELL's cost and schedule performance on this overseas project and potential follow-on State Department awards.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 16, 2026

The single high-value federal grant analyzed, totaling $378.1 million, is a civilian Department of State award to CADDELL CONSTRUCTION CO. (DE), LLC for embassy construction in Brasilia, Brazil, with no defense-related contracts in this period. The dominant theme is stable, long-term civilian infrastructure investment, but the neutral signal and medium execution risk from the firm-fixed-price overseas contract temper enthusiasm. The highest-conviction signal is the seven-year revenue visibility for CADDELL, though investors should watch for cost overruns or schedule delays that could compress margins. Key risk is the fixed-price nature of the contract, which exposes CADDELL to cost overruns in a foreign construction environment.

1 total filings
· daily

General Federal Contracts — September 16, 2026

This digest covers a single, large $378.1 million firm-fixed-price contract awarded to CADDELL CONSTRUCTION CO. (DE), LLC by the Department of State for a new embassy compound in Brasilia, Brazil. The award is entirely civilian (State Department) and represents a long-term, seven-year revenue stream for CADDELL, though it carries execution risk due to its fixed-price nature and overseas location. The neutral signal strength (6/10) reflects the balance between stable revenue visibility and the inherent risks of large-scale international construction. The key watch item is CADDELL's ability to execute on cost and schedule, as any overruns would directly impact profitability.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 16, 2026

The 11 filings for the S&P 500 Technology sector on September 16, 2026, reveal a pronounced insider selling wave, particularly among top executives at KLA Corp, Synopsys, Fortinet, and Datadog, with aggregate sales exceeding $30 million. This pattern suggests a broad de-risking by management, potentially ahead of sector headwinds or to lock in gains after a strong run. While most sales were executed under Rule 10b5-1 plans, the concentration and size are notable. In contrast, tax-withholding transactions at Salesforce and Marvell Technology are routine and carry no negative signal. The data lacks period-over-period comparisons, forward guidance, or capital allocation details, limiting trend analysis. The primary actionable insight is the high level of insider liquidation, which warrants caution for the sector.

11 high priority 11 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 16, 2026

All 8 filings are Form 4 insider transaction reports from NASDAQ-100 constituents, revealing a concentrated wave of insider selling across mega-cap tech and healthcare. Notably, 5 of 8 filings show insider sales, with Meta's COO, Gilead's CFO, and Booking's CHRO all executing sales under Rule 10b5-1 plans, suggesting pre-planned, not reactive, selling. The selling is primarily by senior executives (C-suite) but at modest dollar amounts relative to holdings, indicating portfolio diversification rather than panic. A counter-trend emerges with insider stock option exercises at PayPal, Intuitive Surgical, and CoreWeave, which can signal confidence in future upside despite tax-related dispositions. No forward-looking guidance, capital allocation changes, or M&A activity were disclosed in these filings, limiting the catalyst calendar. The overall sentiment is cautiously negative, with the pattern of insider selling at elevated valuations (Meta at $657, Intuitive at $374) warranting monitoring, though the scale is not alarming.

7 high priority 1 medium 8 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 16, 2026

The September 16, 2026 batch of 36 filings reveals a bifurcated activist/institutional landscape. Activist managers are deploying capital into beaten-down small/micro-caps (Hepion, VolitionRx, Nuzee) and agitating for board change at larger caps (Vail Resorts, Dynatrace), while several 13Ds show ownership reductions (Comstock, Genco Shipping) and passive 13G filings dominate the institutional flow. Key themes include activist board refreshment campaigns, insider selling into strength (Comstock), and a notable concentration of filings in healthcare and financials. The most actionable signals are the Vail Resorts proxy fight, MIG's strategic investment in Nuzee, and the Gabelli accumulation in Suro Capital.

24 high priority 12 medium 36 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 16, 2026

The 18 filings for the S&P 500 Financials sector are dominated by a single, massive strategic initiative: Morgan Stanley's plan to convert $9.6 billion in Eaton Vance municipal bond mutual funds into ETFs. This theme, spanning 13 filings, signals a major industry shift toward the ETF wrapper for active fixed-income strategies, with Morgan Stanley leveraging its successful conversion track record. While this presents a significant growth catalyst for Morgan Stanley's asset management arm, it also introduces execution risk tied to shareholder votes. Outside this theme, insider selling at Capital One and Aflac, along with routine capital markets activity at Intercontinental Exchange and American Express, provide a more cautious counterpoint. The key period-over-period trend is the absence of traditional financial metrics (revenue, NIM, EPS) in these filings, which are primarily transactional or strategic announcements, limiting the ability to perform standard financial trend analysis. The most critical development is the potential for Morgan Stanley to nearly double its ETF AUM to over $25 billion, a transformative move that could pressure other active asset managers to follow suit.

17 high priority 1 medium 18 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 16, 2026

The five filings, all within the S&P 500 Energy scope, show a sector bifurcating between strategic consolidation and routine governance. Expand Energy's $500M debt offering and the completion of the Twin Eagle acquisition signal a major push into gas marketing and LNG integration, positioning it as a key consolidator. In contrast, ConocoPhillips, Texas Pacific Land, and Halliburton filings are low-materiality, reflecting normal equity compensation, a token insider purchase, and standard board changes, respectively. No period-over-period financial trends (revenue, margins) are available from these filings, limiting quantitative trend analysis. The most actionable insights center on Expand Energy's capital allocation and the potential for near-term price movement around its debt offering and acquisition close. The sector theme is one of strategic repositioning in natural gas value chains, while other names show no operational red flags.

4 high priority 1 medium 5 total filings